🟢 NeOnc Technologies Holdings is trading 11.04% up today after positive NEO100 Phase 2a results

NeOnc Technologies Holdings is trading 11.04% up at $3.44 after executives disclosed approximately $629,000 in open-market purchases following positive NEO100 Phase 2a results.

• CEO Amir Heshmatpour purchased 111,000 shares worth approximately $418,700.
• The study met its primary endpoint and supported plans for a Type B FDA meeting regarding a potential registrational path.
• Broader biotech strength and a market rebound may be providing additional support.